Linked Life Data

15111772

Source:http://linkedlifedata.com/resource/pubmed/id/15111772

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15111772rdf:typepubmed:Citationlld:pubmed
pubmed-article:15111772lifeskim:mentionsumls-concept:C0043210lld:lifeskim
pubmed-article:15111772lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:15111772lifeskim:mentionsumls-concept:C1519429lld:lifeskim
pubmed-article:15111772lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:15111772lifeskim:mentionsumls-concept:C0278488lld:lifeskim
pubmed-article:15111772lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:15111772lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:15111772lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:15111772pubmed:issue2lld:pubmed
pubmed-article:15111772pubmed:dateCreated2004-4-27lld:pubmed
pubmed-article:15111772pubmed:abstractTextTo evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial.lld:pubmed
pubmed-article:15111772pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:languageenglld:pubmed
pubmed-article:15111772pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:citationSubsetIMlld:pubmed
pubmed-article:15111772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15111772pubmed:statusMEDLINElld:pubmed
pubmed-article:15111772pubmed:monthMaylld:pubmed
pubmed-article:15111772pubmed:issn0167-6806lld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:Thomas BuddGGlld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:BalcerzakStan...lld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:LymanGary HGHlld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:MartinoSilvan...lld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:RussellChrist...lld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:GreenStephani...lld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:RavdinPeter...lld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:Geyer...lld:pubmed
pubmed-article:15111772pubmed:authorpubmed-author:Southwest...lld:pubmed
pubmed-article:15111772pubmed:issnTypePrintlld:pubmed
pubmed-article:15111772pubmed:volume85lld:pubmed
pubmed-article:15111772pubmed:ownerNLMlld:pubmed
pubmed-article:15111772pubmed:authorsCompleteYlld:pubmed
pubmed-article:15111772pubmed:pagination143-50lld:pubmed
pubmed-article:15111772pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:meshHeadingpubmed-meshheading:15111772...lld:pubmed
pubmed-article:15111772pubmed:year2004lld:pubmed
pubmed-article:15111772pubmed:articleTitleA Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.lld:pubmed
pubmed-article:15111772pubmed:affiliationJames P. Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY 14642-0001, USA. gary_lyman@urmc.rochester.edulld:pubmed
pubmed-article:15111772pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15111772pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15111772pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15111772pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15111772pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:15111772pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed